Liquid Biopsy Testing
Now offering mobile phlebotomy services
NeoGenomics offers a broad collection of comprehensive, targeted and single gene liquid biopsy assays for solid tumor cancer and hematologic malignancies. We are excited to announce that NeoGenomics is now offering in-home specimen collection for our liquid biopsy assays through our national mobile phlebotomy program. Our goal is to provide all patients access to testing in a timely manner to ensure efficient diagnosis and disease progression monitoring.
InVisionFirst®-Lung
A ctDNA NGS liquid biopsy testing 37 genes relevant to the care of advanced NSCLC patients.
NeoLAB® Solid Tumor Liquid Biopsy
Rapid, high-quality NGS-based genomic profile for pan-cancer.
NeoLAB® Heme Liquid Biopsy
Detection of critical biomarkers in patients with known and suspected hematologic cancers.
National Mobile Phlebotomy Program
Safe and convenient in-home blood draws with no added cost for patients
For more information contact
NeoGenomics Client Services at 1-866-776-5907.
Download the mobile phlebotomy brochure here.
“This in-home service addresses patient fears of exposure to COVID-19, and ensures the efficient continuity of care, which is so crucial in the treatment and monitoring of cancer patients.”
- Douglas VanOort, CEO
Learn how to access our new National Mobile Phlebotomy Service for blood-based tests, to ensure no delays in care for cancer patients.
Liquid biopsy testing helps inform precision decisions by the following:
- Inform treatment strategies
- Monitor disease progression
- Evaluate therapeutic effectiveness
Advantages |
Disadvantages |
|
---|---|---|
Tissue Biopsy |
High diagnostic certainty |
Lack of representativeness of tumor heterogeneity |
Liquid Biopsy |
Can detect tumor heterogeneity |
Cannot detect location of tumor mutations |
Representative analysis of multiple tumor foci |
No diagnostic value if no mutation detected |
PIK3CA Mutation CDx Sponsored Testing Program
Available with liquid biopsy testing
PIK3CA Mutation CDx in Tissue or Plasma is a new biomarker-driven strategy for the detection of the PIK3CA mutation and identification of eligible patients for appropriate therapy.
*InVisionFirst®-Lung is a trademark of Inivata Limited.